Synthetic analogues of bovine bactenecin dodecapeptide reduce herpes simplex virus type 2 infectivity in mice

Antiviral Research

Volumn 100, Issue 2, 2013, Pages 455-459

  Shestakov, Andrey ^a   Jenssen, Håvard ^b,c   Hancock, Robert E W ^b   Nordström, Inger ^a   Eriksson, Kristina ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c ROSKILDE UNIVERSITY   (Denmark)

Author keywords

Antimicrobial peptides; Bovine bactenecin; Genital herpes; HSV 2; Synthetic analogues

Indexed keywords

BACTENECIN DODECAPEPTIDE; BETA DEFENSIN 3; PEPTIDE 1002; PEPTIDE 1006; PEPTIDE 1018; PEPTIDE HH 2; POLYPEPTIDE ANTIBIOTIC AGENT; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; ANTIVIRUS AGENT; BACTENECIN; CYCLOPEPTIDE; GLYCOSAMINOGLYCAN; HEPARAN SULFATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; DISEASE COURSE; DOSE RESPONSE; DRUG EFFICACY; FEMALE; GENITAL HERPES; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 2; HUMAN; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; INOCULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; VERO CELL; VIRUS ATTACHMENT; VIRUS ENTRY; VIRUS INFECTIVITY; VIRUS REPLICATION; AMPS; ANIMAL; ANTI-MICROBIAL PEPTIDES; ANTIMICROBIAL PEPTIDES; BOVINE BACTENECIN; CHEMOPROPHYLAXIS; CHLOROCEBUS AETHIOPS; DISEASE MODEL; DRUG EFFECT; GAG; HDPS; HNP; HOST DEFENSE PEPTIDES; HS; HSV-2; HUMAN NEUTROPHIL PEPTIDES; METHODOLOGY; MICROBIAL SENSITIVITY TEST; PHYSIOLOGY; SYNTHETIC ANALOGUES; TREATMENT OUTCOME; VERO CELL LINE;

BOVINAE; HERPES; HUMAN HERPESVIRUS 2; MUS;

AMPS; ANTI-MICROBIAL PEPTIDES; ANTIMICROBIAL PEPTIDES; BOVINE BACTENECIN; GAG; GENITAL HERPES; GLYCOSAMINOGLYCANS; HDPS; HEPARAN SULFATE; HERPES SIMPLEX VIRUS TYPE 2; HNP; HOST DEFENSE PEPTIDES; HS; HSV-2; HUMAN NEUTROPHIL PEPTIDES; SYNTHETIC ANALOGUES;

ANIMALS; ANTIVIRAL AGENTS; CERCOPITHECUS AETHIOPS; CHEMOPREVENTION; DISEASE MODELS, ANIMAL; HERPES GENITALIS; HERPESVIRUS 2, HUMAN; MICE; MICROBIAL SENSITIVITY TESTS; PEPTIDES, CYCLIC; TREATMENT OUTCOME; VERO CELLS; VIRUS INTERNALIZATION;

EID: 84885465444     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2013.08.019     Document Type: Article

References (45)

1. R.P. Allaker Host defence peptides-a bridge between the innate and adaptive immune responses Trans. R. Soc. Trop. Med. Hyg. 102 2008 3 4
2. G. Andrei, R. Snoeck, and E. De Clerq Differential susceptibility of several drug-resistant strains of herpes simplex virus type 2 to various antiviral compounds Antivir. Chem. Chemother. 8 1997 457 461
3. F. Bai, T. Town, D. Pradhan, J. Cox, Ashish, M. Ledizet, J.F. Anderson, R.A. Flavell, J.K. Krueger, R.A. Koski, and E. Fikrig Antiviral peptides targeting the west nile virus envelope protein J. Virol. 81 2007 2047 2055
4. C.R. Brandt, R. Akkarawongsa, S. Altmann, G. Jose, A.W. Kolb, A.J. Waring, and R.I. Lehrer Evaluation of a theta-defensin in a Murine model of herpes simplex virus type 1 keratitis Invest. Ophthalmol. Vis. Sci. 48 2007 5118 5124
5. C.B. Buck, P.M. Day, C.D. Thompson, J. Lubkowski, W. Lu, D.R. Lowy, and J.T. Schiller Human alpha-defensins block papillomavirus infection Proc. Natl. Acad. Sci. USA 103 2006 1516 1521
6. N.J. Cho, H. Dvory-Sobol, A. Xiong, S.J. Cho, C.W. Frank, and J.S. Glenn Mechanism of an amphipathic alpha-helical peptide's antiviral activity involves size-dependent virus particle lysis ACS Chem. Biol. 4 2009 1061 1067
7. K.A. Daher, M.E. Selsted, and R.I. Lehrer Direct inactivation of viruses by human granulocyte defensins J. Virol. 60 1986 1068 1074
8. R. Duan, R.D. de Vries, A.D. Osterhaus, L. Remeijer, and G.M. Verjans Acyclovir-resistant corneal HSV-1 isolates from patients with herpetic keratitis J. Infect. Dis. 198 2008 659 663
9. M. Egal, M. Conrad, D.L. MacDonald, W.L. Maloy, M. Motley, and C.A. Genco Antiviral effects of synthetic membrane-active peptides on herpes simplex virus, type 1 Int. J. Antimicrob. Agents 13 1999 57 60
10. M. Fatahzadeh, and R.A. Schwartz Human herpes simplex virus infections: epidemiology, pathogenesis, symptomatology, diagnosis, and management J. Am. Acad. Dermatol. 57 2007 737 763 quiz 764-736
11. E.E. Freeman, H.A. Weiss, J.R. Glynn, P.L. Cross, J.A. Whitworth, and R.J. Hayes Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies AIDS 20 2006 73 83
12. E. Frobert, J.C. Cortay, T. Ooka, F. Najioullah, D. Thouvenot, B. Lina, and F. Morfin Genotypic detection of acyclovir-resistant HSV-1: characterization of 67 ACV-sensitive and 14 ACV-resistant viruses Antiviral Res. 79 2008 28 36
13. Y.J. Gordon, L.C. Huang, E.G. Romanowski, K.A. Yates, R.J. Proske, and A.M. McDermott Human cathelicidin (LL-37), a multifunctional peptide, is expressed by ocular surface epithelia and has potent antibacterial and antiviral activity Curr. Eye Res. 30 2005 385 394
14. B. Halioua, and J.E. Malkin Epidemiology of genital herpes - recent advances Eur. J. Dermatol. 9 1999 177 184
15. E. Hazrati, B. Galen, W. Lu, W. Wang, Y. Ouyang, M.J. Keller, R.I. Lehrer, and B.C. Herold Human alpha- and beta-defensins block multiple steps in herpes simplex virus infection J. Immunol. 177 2006 8658 8666
16. K. Hilpert, R. Volkmer-Engert, T. Walter, and R.E. Hancock High-throughput generation of small antibacterial peptides with improved activity Nat Biotechnol 23 2005 1008 1012
17. M.D. Howell, A. Wollenberg, R.L. Gallo, M. Flaig, J.E. Streib, C. Wong, T. Pavicic, M. Boguniewicz, and D.Y. Leung Cathelicidin deficiency predisposes to eczema herpeticum J. Allergy Clin. Immunol. 117 2006 836 841
18. H. Jenssen, J.H. Andersen, D. Mantzilas, and T.J. Gutteberg A wide range of medium-sized, highly cationic, alpha-helical peptides show antiviral activity against herpes simplex virus Antiviral Res. 64 2004 119 126
19. H. Jenssen, J.H. Andersen, L. Uhlin-Hansen, T.J. Gutteberg, and O. Rekdal Anti-HSV activity of lactoferricin analogues is only partly related to their affinity for heparan sulfate Antiviral Res. 61 2004 101 109
20. H. Jenssen, P. Hamill, and R.E.W. Hancock Peptide antimicrobial agents Clin. Microbiol. Rev. 19 2006 491 511
21. M. John, M.J. Keller, E.H. Fam, N. Cheshenko, K. Hogarty, A. Kasowitz, S. Wallenstein, M.J. Carlucci, A.C. Tuyama, W. Lu, M.E. Klotman, R.I. Lehrer, and B.C. Herold Cervicovaginal secretions contribute to innate resistance to herpes simplex virus infection J. Infect. Dis. 192 2005 1731 1740
22. J. Kindrachuk, H. Jenssen, M. Elliott, R. Townsend, A. Nijnik, S.F. Lee, V. Gerdts, L.A. Babiuk, S.A. Halperin, and R.E. Hancock A novel vaccine adjuvant comprised of a synthetic innate defence regulator peptide and CpG oligonucleotide links innate and adaptive immunity Vaccine 27 2009 4662 4671
23. M. Krepstakies, J. Lucifora, C.H. Nagel, M.B. Zeisel, B. Holstermann, H. Hohenberg, I. Kowalski, T. Gutsmann, T.F. Baumert, K. Brandenburg, J. Hauber, and U. Protzer A new class of synthetic peptide inhibitors blocks attachment and entry of human pathogenic viruses J. Infect. Dis. 205 2012 1654 1664
24. E. Leikina, H. Delanoe-Ayari, K. Melikov, M.S. Cho, A. Chen, A.J. Waring, W. Wang, Y. Xie, J.A. Loo, R.I. Lehrer, and L.V. Chernomordik Carbohydrate-binding molecules inhibit viral fusion and entry by crosslinking membrane glycoproteins Nat. Immunol. 6 2005 995 1001
25. A. Luganini, S.F. Nicoletto, L. Pizzuto, G. Pirri, A. Giuliani, S. Landolfo, and G. Gribaudo Inhibition of herpes simplex virus type 1 and 2 infection by peptide-derivatized dendrimers 2011 Antimicrob. Agents Chemother.
26. K.V. Mohan, S.S. Rao, and C.D. Atreya Antiviral activity of selected antimicrobial peptides against vaccinia virus Antiviral Res. 86 2010 306 311
27. L.A. Morrison, X.J. Da Costa, and D.M. Knipe Influence of mucosal and parenteral immunization with a replication-defective mutant of HSV-2 on immune responses and protection from genital challenge Virology 243 1998 178 187
28. L. Namvar, S. Olofsson, T. Bergstrom, and M. Lindh Detection and typing of Herpes Simplex virus (HSV) in mucocutaneous samples by TaqMan PCR targeting a gB segment homologous types HSV for 1 and 2 J Clin Microbiol 43 2005 2058 2064
29. A. Nijnik, L. Madera, S. Ma, M. Waldbrook, M.R. Elliott, D.M. Easton, M.L. Mayer, S.C. Mullaly, J. Kindrachuk, H. Jenssen, and R.E. Hancock Synthetic cationic peptide IDR-1002 provides protection against bacterial infections through chemokine induction and enhanced leukocyte recruitment J. Immunol. 184 2010 2539 2550
30. M.B. Parr, L. Kepple, M.R. McDermott, M.D. Drew, J.J. Bozzola, and E.L. Parr A mouse model for studies of mucosal immunity to vaginal infection by herpes simplex virus type 2 Lab. Invest. 70 1994 369 380
31. M. Reyes, N.S. Shaik, J.M. Graber, R. Nisenbaum, N.T. Wetherall, K. Fukuda, and W.C. Reeves Acyclovir-resistant genital herpes among persons attending sexually transmitted disease and human immunodeficiency virus clinics Arch. Intern. Med. 163 2003 76 80
32. O. Scudiero, S. Galdiero, M. Cantisani, R. Di Noto, M. Vitiello, M. Galdiero, G. Naclerio, J.J. Cassiman, C. Pedone, G. Castaldo, and F. Salvatore Novel synthetic, salt-resistant analogs of human beta-defensins 1 and 3 endowed with enhanced antimicrobial activity Antimicrob. Agents Chemother. 54 2010 2312 2322
33. M.E. Selsted, and A.J. Ouellette Mammalian defensins in the antimicrobial immune response Nat. Immunol. 6 2005 551 557
34. G.F. Shust, S. Cho, M. Kim, R.P. Madan, E.M. Guzman, M. Pollack, J. Epstein, H.W. Cohen, M.J. Keller, and B.C. Herold Female genital tract secretions inhibit herpes simplex virus infection: correlation with soluble mucosal immune mediators and impact of hormonal contraception Am. J. Reprod. Immunol. 63 2010 110 119
35. S. Sinha, N. Cheshenko, R.I. Lehrer, and B.C. Herold NP-1, a rabbit alpha-defensin, prevents the entry and intercellular spread of herpes simplex virus type 2 Antimicrob. Agents Chemother. 47 2003 494 500
36. L. Steinstraesser, B. Tippler, J. Mertens, E. Lamme, H.H. Homann, M. Lehnhardt, O. Wildner, H.U. Steinau, and K. Uberla Inhibition of early steps in the lentiviral replication cycle by cathelicidin host defense peptides Retrovirology 2 2005 2
37. S.K. Straus, and R.E.W. Hancock Mode of action of the new antibiotic for gram-positive pathogens daptomycin: comparison with cationic antimicrobial peptides and lipopeptides Biochim. Biophys. Acta 1758 2006 1215 1223
38. L.B. Strick, A. Wald, and C. Celum Management of herpes simplex virus type 2 infection in HIV type 1-infected persons Clin. Infect. Dis. 43 2006 347 356
39. M. Wieczorek, H. Jenssen, J. Kindrachuk, W.R. Scott, M. Elliott, K. Hilpert, J.T. Cheng, R.E. Hancock, and S.K. Straus Structural studies of a peptide with immune modulating and direct antimicrobial activity Chem. Biol. 17 2010 970 980
40. J. Wiesner, and A. Vilcinskas Antimicrobial peptides: the ancient arm of the human immune system Virulence 1 2010 440 464
41. D. WuDunn, and P.G. Spear Initial interaction of herpes simplex virus with cells is binding to heparan sulfate J. Virol. 63 1989 52 58
42. B. Yasin, M. Pang, J.S. Turner, Y. Cho, N.N. Dinh, A.J. Waring, R.I. Lehrer, and E.A. Wagar Evaluation of the inactivation of infectious herpes simplex virus by host-defense peptides Eur. J. Clin. Microbiol. Infect. Dis. 19 2000 187 194
43. B. Yasin, W. Wang, M. Pang, N. Cheshenko, T. Hong, A.J. Waring, B.C. Herold, E.A. Wagar, and R.I. Lehrer Theta defensins protect cells from infection by herpes simplex virus by inhibiting viral adhesion and entry J. Virol. 78 2004 5147 5156
44. A.T. Yeung, S.L. Gellatly, and R.E.W. Hancock Multifunctional cationic host defence peptides and their clinical applications Cell. Mol. Life Sci. 68 2011 2161 2176
45. M. Zanetti Cathelicidins, multifunctional peptides of the innate immunity J. Leukoc. Biol. 75 2004 39 48